Bioceres price target lowered to $5 from $8 at Lake Street

Group 1 - Lake Street analyst Ben Klieve lowered the price target on Bioceres (BIOX) to $5 from $8 while maintaining a Buy rating on the shares [1] - Q4 results were significantly below all estimates across each segment, indicating potential challenges for the company [1] - The firm anticipates that FY25 will represent an EBITDA trough and sees value in the next-generation products within Bioceres' portfolio [1]